Hi there!
We track 70,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!

Ataraxis AI provides clinicians with AI-driven prognostic and predictive diagnostics to guide cancer treatment selection and personalize care. The company analyzes multi-modal patient data—including…

Ataraxis AI provides clinicians with AI-driven prognostic and predictive diagnostics to guide cancer treatment selection and personalize care. The company analyzes multi-modal patient data—including…
What they do: AI-driven prognostic and predictive diagnostics to guide cancer treatment and personalize care
Flagship product: Ataraxis Breast — AI-native prognostic test for breast cancer (clinically validated)
Stage & funding: Clinical-stage; $20.4M Series A announced March 5, 2025 (prior $4M seed)
Origins: Spun out of New York University (founded 2023)
Founders / leadership: Jan Witowski, MD PhD (CEO & Co‑founder); Krzysztof Geras, PhD (Chief Scientist & Co‑founder)
Cancer diagnostics and precision oncology; prognostic and predictive testing to guide treatment selection
2023
Biotechnology
4000000
Seed round following NYU spinout
20400000
Series A to accelerate clinical deployment; participation from Thiel Bio, Founders Fund, Floating Point, Bertelsmann Investments, Giant Ventures, Obvious Ventures, and angel/strategic backers
“AIX Ventures led Series A with participation from well‑known healthcare and AI investors (Thiel Bio, Founders Fund, Floating Point, Bertelsmann Investments, Giant Ventures, Obvious Ventures) and angel/strategic backers”
Your next opportunity is in here somewhere. Sign up to explore 70,000+ startups and their open roles. No spam. No gamification. Just jobs.
70,000+
Startups
81,000+
Open Roles
4,600+
New This Week
| Company |
|---|